EFL

Role: Mentor

Tracks: Life Sciences

Stephen Chang

Strategic Partner, Cell One Partners

Dr. Stephen Chang has dedicated over three and half decades to pushing the boundaries of scientific innovation and bringing breakthrough treatments to patients in need. Through his leadership, Stephen has successfully navigated the complexities of drug development and commercialization, with a focus on cutting-edge technologies such as gene therapy, mRNA vaccine development, stem cell technologies and complex biologicals. Stephen record of accomplishment speaks for itself, with two recent drug successes that have made a significant impact in the field of medicine. Adstilirin TM- rAd-ifn/ syn3, approved in December 2022 for bladder cancer therapy using gene therapy, and Intravail TMdiazepam, approved for epilepsy treatment through novel drug delivery. These are just a few examples of the groundbreaking work that has come out of Stephen laboratory or through his direct involvement. Stephen experience as a researcher, entrepreneur, teacher, and scientific and business leader has equipped him with the skills necessary to navigate the challenges of the life sciences industry and bring transformative therapies to market. Stephen is a firm believer in the power of teamwork and diversity. Through his career of collaboration and access to different patient and stakeholder perspectives that we can truly drive innovation and make a difference in the lives of patients. Stephen is a recognized pioneer in commercial gene therapy technologies and induced pluripotent stem cells, he is well-versed in the intricacies of drug development and have a proven record of accomplishment of success. He is also adept at navigating the political landscape and effectively communicating complex scientific concepts to a wide range of audiences. In summary, Stephen passion for biotechnology and driving scientific innovation, coupled with my experience in drug development and commercialization, make me an asset in the life sciences industry. He looks forward to continuing to push the boundaries of what is possible in the field of medicine and making a lasting impact on the lives of patients around the world Stephen graduated from Michigan with BS in four scientific disciplines, a Phd from University of California, Irvine in Biological Chemistry. Currently Stephen is on the Boards of private companies Mirimus, Virtus and Diodem. He is slotted to join an upcoming IPO company as an independent director.